Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Prostatic Neoplasms"" wg kryterium: Temat


Tytuł:
The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance.
Autorzy:
Liu A; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Gao Y; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Wang Q; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Lin W; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Ma Z; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Yang X; Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. .
Chen L; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China. .
Xu D; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Sep 19; Vol. 21 (1), pp. 641. Date of Electronic Publication: 2023 Sep 19.
Typ publikacji:
Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Clonal Evolution*/genetics
Prostatic Neoplasms*/genetics
Humans ; Male ; Androgen Antagonists ; Androgens ; Tumor Microenvironment ; East Asian People ; Prostatic Neoplasms, Castration-Resistant
Czasopismo naukowe
Tytuł:
Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Autorzy:
Qi F; Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Xu Z; Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Electronic address: .
Zou Q; Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Pokaż więcej
Źródło:
European urology [Eur Urol] 2023 Mar; Vol. 83 (3), pp. e76-e77. Date of Electronic Publication: 2023 Jan 03.
Typ publikacji:
Letter; Comment
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/genetics
Genes, BRCA1*
Genes, BRCA2*
Humans ; Male ; Abiraterone Acetate ; Indoles ; Mutation ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics
Opinia redakcyjna
Tytuł:
Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Autorzy:
Loehr A; Translational Medicine, Clovis Oncology, Boulder, CO, USA.
Chowdhury S; Medical Oncology, Guy's Hospital, London, UK; Sarah Cannon Research Institute, London, UK.
Abida W; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: .
Pokaż więcej
Źródło:
European urology [Eur Urol] 2023 Mar; Vol. 83 (3), pp. e78. Date of Electronic Publication: 2023 Jan 07.
Typ publikacji:
Letter; Comment
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/genetics
Humans ; Male ; Indoles ; Mutation ; Prostatic Neoplasms ; Genes, BRCA1 ; Genes, BRCA2
Opinia redakcyjna
Tytuł:
CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer.
Autorzy:
Zhang N; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huang D; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ruan X; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ng AT; Division of Urology, Department of Surgery, Queen Mary Hospital, Hong Kong, China; Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Tsu JH; Division of Urology, Department of Surgery, Queen Mary Hospital, Hong Kong, China; Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Jiang G; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huang J; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhan Y; Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Na R; Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: .
Pokaż więcej
Źródło:
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy [Drug Resist Updat] 2023 Mar; Vol. 67, pp. 100912. Date of Electronic Publication: 2023 Jan 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/genetics
Prostatic Neoplasms, Castration-Resistant*/pathology
Ubiquitin-Protein Ligases*/genetics
Humans ; Male ; ATPases Associated with Diverse Cellular Activities/genetics ; ATPases Associated with Diverse Cellular Activities/metabolism ; ATPases Associated with Diverse Cellular Activities/therapeutic use ; Cell Cycle Proteins/genetics ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Clustered Regularly Interspaced Short Palindromic Repeats ; CRISPR-Cas Systems ; Early Detection of Cancer ; High-Throughput Screening Assays ; Neoplasm Grading ; Prostatic Neoplasms/genetics ; Proteomics ; Ubiquitins/genetics ; Ubiquitins/metabolism ; Ubiquitins/therapeutic use
Czasopismo naukowe
Tytuł:
Kidney transplantation in prostate cancer patients after local therapy with curative intent: a systematic review.
Autorzy:
Rumpff C; Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Lieb V; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstraße 12, 91054, Erlangen, Germany.; Transplant Centre Erlangen-Nürnberg, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstraße 12, 91054, Erlangen, Germany.; Transplant Centre Erlangen-Nürnberg, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Schiffer M; Transplant Centre Erlangen-Nürnberg, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Kunath F; Klinik für Urologie und Kinderurologie, Klinikum Bayreuth GmbH, Bayreuth, Germany.; Medizinische Fakultät am Medizincampus Oberfranken, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland.
Apel H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstraße 12, 91054, Erlangen, Germany. .; Transplant Centre Erlangen-Nürnberg, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. .
Pokaż więcej
Źródło:
World journal of urology [World J Urol] 2024 Mar 09; Vol. 42 (1), pp. 127. Date of Electronic Publication: 2024 Mar 09.
Typ publikacji:
Systematic Review; Journal Article
MeSH Terms:
Kidney Transplantation*/adverse effects
Prostatic Neoplasms*/surgery
Prostatic Neoplasms*/etiology
Male ; Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Autorzy:
Shore ND; Carolina Urologic Research Center/Genesis Care, Myrtle Beach, SC, USA.
Hussain M; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Saad F; Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, Quebec, Canada.
Fizazi K; Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Department of Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York, NY, USA.
Crawford D; University of California San Diego School of Medicine, San Diego, CA, USA.
Tombal B; Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium.
Nordquist L; XCancer/GU Research Network, Omaha, NE, USA.
Cookson M; University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.
Verholen F; Bayer Consumer Care, Basel, Switzerland.
Jhaveri J; Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, USA.
Srinivasan S; Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, USA.
Smith MR; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Mar 04; Vol. 29 (3), pp. 235-243.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Pyrazoles*
Humans ; Male ; Androgen Antagonists/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Docetaxel/therapeutic use ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł:
Analysis of trend in the role of national and regional hubs in prostatectomy after prostate cancer diagnosis in the past 5 years: A nationwide population-based study.
Autorzy:
Kim SC; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.; Basic-Clinical Convergence Research Center, University of Ulsan, Ulsan, Korea.
Han S; Department of Biostatistics, Korea University College of Medicine, Seoul, Korea.
Yoon JH; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Park S; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.; Basic-Clinical Convergence Research Center, University of Ulsan, Ulsan, Korea.
Moon KH; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Cheon SH; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Park GM; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Kwon T; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. .
Pokaż więcej
Źródło:
Investigative and clinical urology [Investig Clin Urol] 2024 Mar; Vol. 65 (2), pp. 124-131.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/surgery
Prostatic Neoplasms*/pathology
Male ; Humans ; Adolescent ; Adult ; Prostatectomy ; Seoul
Czasopismo naukowe
Tytuł:
Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.
Autorzy:
Lee JN; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim MY; Department of Radiation Oncology, Kyungpook National University Chilgok Hospital, Daegu, Korea.
Kang JH; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kang JK; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Chung JW; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Ha YS; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Choi SH; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim BS; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim HT; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim TH; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Yoo ES; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim SH; Department of Radiology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kwon TG; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. .
Pokaż więcej
Źródło:
Investigative and clinical urology [Investig Clin Urol] 2024 Mar; Vol. 65 (2), pp. 132-138.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Male ; Humans ; Retrospective Studies ; Treatment Outcome ; Progression-Free Survival
Czasopismo naukowe
Tytuł:
Combined MRI-TRUS fusion targeted and systematic biopsy versus systematic biopsy alone for the detection of prostate cancer: protocol for a prospective single-centre trial.
Autorzy:
Liu W; Department of Pathology, Shanghai Tenth People's Hospital, Shanghai, China.; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Kadier A; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.; Department of Urology, Shanghai Tenth People's Hospital, Shanghai, China.
Shen D; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.; Department of Urology, Shanghai Tenth People's Hospital, Shanghai, China.
He Y; Department of Pathology, Shanghai Tenth People's Hospital, Shanghai, China.; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Dong S; Department of Pathology, Shanghai Tenth People's Hospital, Shanghai, China.; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Zhu K; Department of Pathology, Shanghai Tenth People's Hospital, Shanghai, China.; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Xu G; Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Shanghai, China.
Zhao B; Department of Radiology, Shanghai Tenth People's Hospital, Shanghai, China.
Mao S; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.; Department of Urology, Shanghai Tenth People's Hospital, Shanghai, China.
Guo C; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.; Department of Urology, Shanghai Tenth People's Hospital, Shanghai, China.
Yao X; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.; Department of Urology, Shanghai Tenth People's Hospital, Shanghai, China.
Wei Q; Department of Pathology, Shanghai Tenth People's Hospital, Shanghai, China.
Han D; Department of Pathology, Shanghai Tenth People's Hospital, Shanghai, China _.
Yang B; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China _.; Department of Urology, Shanghai Tenth People's Hospital, Shanghai, China.
Pokaż więcej
Źródło:
BMJ open [BMJ Open] 2024 Mar 01; Vol. 14 (3), pp. e080593. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Image-Guided Biopsy*/methods
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/pathology
Humans ; Male ; China ; Magnetic Resonance Imaging/methods ; Prospective Studies
Czasopismo naukowe
Tytuł:
Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study.
Autorzy:
Roy S; Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA. Electronic address: .
Saad F; Department of Surgery, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Wallis CJD; Department of Urology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.
Sun Y; Case Western Reserve University, Cleveland, OH, USA.
Spratt DE; Department of Radiation Oncology, University Hospitals, Seidman Cancer Center, Cleveland, OH, USA.
Akilla R; University of Houston, Houston, TX, USA.
Kishan AU; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Malone S; Department of Radiology, Radiation Oncology and Medical Physics, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada.
Morgan SC; Department of Radiology, Radiation Oncology and Medical Physics, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. Electronic address: .
Pokaż więcej
Źródło:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Mar; Vol. 199, pp. 113348. Date of Electronic Publication: 2023 Sep 20.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms*
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Male ; Humans ; Androgen Antagonists/therapeutic use ; Abiraterone Acetate/therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Aspirin/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Administering [ Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
Autorzy:
Eapen RS; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: .
Buteau JP; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
Jackson P; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Australia.
Mitchell C; Department of Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Oon SF; Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
Alghazo O; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
McIntosh L; Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
Dhiantravan N; Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
Scalzo MJ; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
O'Brien J; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Sandhu S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Azad AA; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Williams SG; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Sharma G; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia.
Haskali MB; Radiopharmaceutical Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.
Bressel M; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia.
Chen K; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Jenjitranant P; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
McVey A; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia.
Moon D; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Lawrentschuk N; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Neeson PJ; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
Murphy DG; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Hofman MS; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
Pokaż więcej
Źródło:
European urology [Eur Urol] 2024 Mar; Vol. 85 (3), pp. 217-226. Date of Electronic Publication: 2023 Oct 26.
Typ publikacji:
Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Prostatic Neoplasms*/surgery
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/pathology
Dipeptides*
Heterocyclic Compounds, 1-Ring*
Male ; Humans ; Prostate-Specific Antigen ; Prostate/pathology ; Positron Emission Tomography Computed Tomography/methods ; Gallium Radioisotopes ; Prostatectomy/methods ; Lutetium/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Novel hormonal therapy versus standard of care-A registry-based comparative effectiveness evaluation for mCRPC-patients.
Autorzy:
Jonéus P; Department of Statistics, Uppsala University, Uppsala, Sweden.
Johansson P; Department of Statistics, Uppsala University, Uppsala, Sweden.; Centre for Health-Economic Research, Uppsala University, Uppsala, Sweden.; YMSC, Tsinghua University, Beijing, China.
Langenskiöld S; Centre for Health-Economic Research, Uppsala University, Uppsala, Sweden.; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Feb 14; Vol. 19 (2), pp. e0290833. Date of Electronic Publication: 2024 Feb 14 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms*/pathology
Male ; Humans ; Standard of Care ; Quality of Life ; Docetaxel/therapeutic use ; Androgen Antagonists/adverse effects
Czasopismo naukowe
Tytuł:
Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Autorzy:
Cevatemre B; Koc University Research Center for Translational Medicine, Istanbul, Turkey.
Bulut I; Koc University Graduate School of Health Sciences, Istanbul, Turkey.
Dedeoglu B; Koc University Graduate School of Science and Engineering, Istanbul, Turkey.
Isiklar A; Koc University Graduate School of Health Sciences, Istanbul, Turkey.
Syed H; Koc University Research Center for Translational Medicine, Istanbul, Turkey.; Koc University School of Medicine, Sariyer, Turkey.
Bayram OY; Koc University Research Center for Translational Medicine, Istanbul, Turkey.
Bagci-Onder T; Koc University Research Center for Translational Medicine, Istanbul, Turkey.; Koc University School of Medicine, Sariyer, Turkey.
Acilan C; Koc University Research Center for Translational Medicine, Istanbul, Turkey. .; Koc University School of Medicine, Sariyer, Turkey. .
Pokaż więcej
Źródło:
Cell death & disease [Cell Death Dis] 2024 Feb 12; Vol. 15 (2), pp. 132. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/genetics
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/genetics
Prostatic Neoplasms, Castration-Resistant*/pathology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Bridged-Ring Compounds*
Male ; Humans ; Taxoids/pharmacology ; Taxoids/therapeutic use ; Docetaxel/pharmacology ; Docetaxel/therapeutic use ; Epigenesis, Genetic ; Drug Resistance, Neoplasm/genetics ; Cell Line, Tumor ; Bromodomain Containing Proteins ; DNA-Binding Proteins/genetics ; Adaptor Proteins, Signal Transducing/genetics ; Protein-Arginine N-Methyltransferases/genetics
Czasopismo naukowe
Tytuł:
Prostate Cancer and the Mevalonate Pathway.
Autorzy:
Guerrero-Ochoa P; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain.
Rodríguez-Zapater S; Minimally Invasive Research Group (GITMI), Faculty of Veterinary Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Anel A; Department of Biochemistry and Molecular and Cellular Biology, Faculty of Sciences, University of Zaragoza, 50009 Zaragoza, Spain.
Esteban LM; Department of Applied Mathematics, Escuela Universitaria Politécnica de La Almunia, Institute for Biocomputation and Physic of Complex Systems, Universidad de Zaragoza, 50100 La Almunia de Doña Godina, Spain.
Camón-Fernández A; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain.
Espilez-Ortiz R; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain.; Department of Urology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.; Area of Urology, Department of Surgery, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Gil-Sanz MJ; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain.; Department of Urology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Borque-Fernando Á; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain.; Department of Applied Mathematics, Escuela Universitaria Politécnica de La Almunia, Institute for Biocomputation and Physic of Complex Systems, Universidad de Zaragoza, 50100 La Almunia de Doña Godina, Spain.; Department of Urology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.; Area of Urology, Department of Surgery, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 10; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/pathology
Prostatic Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Male ; Humans ; Mevalonic Acid ; Receptors, Androgen/metabolism
Czasopismo naukowe
Tytuł:
PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling.
Autorzy:
Yang T; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Urology, The Third People's Hospital of Chengdu/The Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan, China.
Chi Y; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Wang X; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Xu C; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Chen X; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Liu Y; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Huang S; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhu X; Department of Pathology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhang H; Department of Pathology, Baoshan Branch, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhuo H; Department of Urology, The Third People's Hospital of Chengdu/The Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan, China. .
Wu D; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. .
Pokaż więcej
Źródło:
Cell death & disease [Cell Death Dis] 2024 Feb 10; Vol. 15 (2), pp. 128. Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Prostatic Hyperplasia*/genetics
Prostatic Neoplasms, Castration-Resistant*
Prostatic Neoplasms*/pathology
Male ; Humans ; Prolactin/genetics ; Prolactin/metabolism ; Receptors, Prolactin/metabolism ; Phosphorylation ; Cell Line, Tumor ; STAT5 Transcription Factor/genetics ; STAT5 Transcription Factor/metabolism ; beta-Arrestin 2/metabolism
Czasopismo naukowe
Tytuł:
Prostate cancer presentation and management in the Middle East.
Autorzy:
Sayan M; Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. .; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. .
Langoe A; Boston College, Boston, MA, USA.
Aynaci O; Karadeniz Technical University, Trabzon, Türkiye, Turkey.
Eren AA; Kartal Dr. Lütfi Kirdar Education and Research Hospital, Istanbul, Turkey.
Eren MF; Marmara University, Istanbul Pendik Education and Research Hospital, Istanbul, Türkiye, Turkey.
Kazaz IO; Karadeniz Technical University, Trabzon, Türkiye, Turkey.
Ibrahim Z; King Hamad University Hospital, Al Sayh, Bahrain.
Al-Akelie OT; Alamal National Hospital for Cancer Management, Baghdad, Iraq.
Al-Mansouri L; Basrah Medical College, Basra, Iraq.
Abu-Hijlih R; King Hussein Cancer Center, Amman, Jordan.
Moningi S; Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Abou Chawareb E; American University of Beirut Medical Center, Beirut, Lebanon.
El Hajj A; American University of Beirut Medical Center, Beirut, Lebanon.
Orio PF; Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Mula-Hussain L; Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.; College of Medicine, Ninevah University, Mosul, Ninevah, Iraq.
Pokaż więcej
Źródło:
BMC urology [BMC Urol] 2024 Feb 09; Vol. 24 (1), pp. 35. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/epidemiology
Prostatic Neoplasms*/therapy
Male ; Humans ; Retrospective Studies ; Iraq ; Lebanon/epidemiology ; Neoplasm Staging
Czasopismo naukowe
Tytuł:
Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH.
Autorzy:
Guerrios-Rivera L; Urology Section, Surgery Department, Veterans Administration Caribbean Healthcare System, San Juan, Puerto Rico.; University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
Janes JL; Section of Urology, Division of Surgery, Durham VA Health Care System, Durham, North Carolina, USA.
De Hoedt AM; Section of Urology, Division of Surgery, Durham VA Health Care System, Durham, North Carolina, USA.
Klaassen Z; Department of Surgery, Section of Urology, Augusta University - Medical College of Georgia, Augusta, Georgia, USA.; Charlie Norwood VA Medical Center, Augusta, Georgia, USA.
Terris MK; Department of Surgery, Section of Urology, Augusta University - Medical College of Georgia, Augusta, Georgia, USA.; Charlie Norwood VA Medical Center, Augusta, Georgia, USA.
Cooperberg MR; Department of Urology, Diller Family Comprehensive Cancer Center, UCSF Helen, San Francisco, California, USA.
Amling CL; Department of Urology, Oregon Health and Science University School of Medicine, Portland, Oregon, USA.
Kane CJ; Department of Urology, UC San Diego Health System, San Diego, California, USA.; VA San Diego Healthcare System, San Diego, California, USA.
Aronson WJ; Department of Urology, UCLA Medical Center, Los Angeles, California, USA.; Wadsworth VA Medical Center, Los Angeles, California, USA.
Fowke JH; Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Division of Epidemiology, Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Freedland SJ; Section of Urology, Division of Surgery, Durham VA Health Care System, Durham, North Carolina, USA.; Center for Integrated Research in Cancer and Lifestyle, Division of Urology, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (4), pp. e7012.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*
Prostatic Neoplasms*/pathology
Male ; Humans ; Extranodal Extension ; Prostatectomy/methods ; Treatment Outcome ; Prostate-Specific Antigen ; Hispanic or Latino ; Neoplasm Recurrence, Local/surgery ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Impact of PSMA PET on Prostate Cancer Management.
Autorzy:
Weiner AB; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. .; Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA. .
Agrawal R; Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA.; Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA.
Valle LF; Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.; Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Sonni I; Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.; Department of Clinical and Experimental Medicine, University Magna Graecia, Catanzaro, Italy.
Kishan AU; Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Rettig MB; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.; Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Raman SS; Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Calais J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Boutros PC; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.; Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA.; Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA.
Reiter RE; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA.
Pokaż więcej
Źródło:
Current treatment options in oncology [Curr Treat Options Oncol] 2024 Feb; Vol. 25 (2), pp. 191-205. Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antigens, Surface*
Prostatic Neoplasms*/therapy
Prostatic Neoplasms*/drug therapy
Humans ; Male ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography/methods ; Prospective Studies ; Radiopharmaceuticals/therapeutic use ; Prostate-Specific Antigen
Czasopismo naukowe
Tytuł:
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
Autorzy:
Lara PN Jr; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA. Electronic address: .
Mayerson E; SWOG Statistical Center, Seattle, WA, USA.
Gertz E; US Department of Agriculture, Western Human Nutrition Research Center, University of California Davis, Davis, CA, USA.
Tangen C; SWOG Statistical Center, Seattle, WA, USA.
Goldkorn A; USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
van Loan M; US Department of Agriculture, Western Human Nutrition Research Center, University of California Davis, Davis, CA, USA.
Hussain M; Northwestern University, Chicago, IL, USA.
Gupta S; Cleveland Clinic, Cleveland, OH, USA.
Zhang J; Moffit Cancer Institute, Tampa Bay, FL, USA.
Parikh M; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Twardowski P; St. John's Cancer Institute, Providence Health, Santa Monica, CA, USA.
Quinn DI; USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
LeBlanc M; SWOG Statistical Center, Seattle, WA, USA.
Vogelzang NJ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
Thompson I; Christus Santa Rosa Health System, San Antonio, TX Health, San Antonio, TX, USA.
Agarwal N; Huntsman Cancer Institute, Salt Lake City, UT, USA.
Pokaż więcej
Źródło:
European urology [Eur Urol] 2024 Feb; Vol. 85 (2), pp. 171-176. Date of Electronic Publication: 2023 Apr 19.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article
MeSH Terms:
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Imidazoles*
Naphthalenes*
Male ; Humans ; Androgen Antagonists/adverse effects ; Androgens/therapeutic use ; Biomarkers ; Biomarkers, Tumor
Czasopismo naukowe
Tytuł:
HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol.
Autorzy:
Mathier E; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Althaus A; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Zwahlen D; Department of Radiation Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
Lustenberger J; Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland.
Zamboglou C; German Oncology Center, European University Cyprus, Limassol, Cyprus.
De Bari B; Department of Radiation Oncology, Réseau hospitalier neuchâtelois, Neuchatel, Switzerland.
Aebersold DM; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Guckenberger M; University Hospital Zurich, Zurich, Switzerland.
Zilli T; Department of Radiation Oncology, Oncological Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.; Università della Svizzera italiana, Lugano, Switzerland.
Shelan M; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland .
Pokaż więcej
Źródło:
BMJ open [BMJ Open] 2024 Jan 30; Vol. 14 (1), pp. e075846. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Prostate*/diagnostic imaging
Prostate*/surgery
Prostate*/pathology
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/radiotherapy
Prostatic Neoplasms*/surgery
Male ; Humans ; Treatment Outcome ; Androgen Antagonists/therapeutic use ; Positron Emission Tomography Computed Tomography/methods ; Prospective Studies ; Quality of Life ; Neoplasm Recurrence, Local/pathology ; Prostatectomy ; Salvage Therapy/methods ; Prostate-Specific Antigen ; Multicenter Studies as Topic ; Clinical Trials, Phase II as Topic
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies